News

Directorate Change

London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor MacRae...

Final Results for the Year Ended 31 December 2019

Tiziana Life Sciences PLC ("Tiziana" or the "Company") Final Results for the Year Ended 31 December 2019 London / New York 18 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the "Company" or "Tiziana"), the U.S. and U.K. biotechnology company that...

Extension of At the Market Sales Agreement

Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the agreement of an extension to the current At the Market Sales Agreement with ThinkEquity, a division of Fordham Financial Management, Inc. As previously announced on 15 April 2020, Tiziana Life Sciences...

Exercise of Warrants and Issue of Equity and Total Voting Rights

London, New York, 2 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...

Appointment of Broker

FOR IMMEDIATE RELEASE 1 June 2020 Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effect. Enquiries: Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 Cairn Financial...

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences Plc 1b. Please...

Exercise of Warrants and Issue of Equity

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...

Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to OncotypeDX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at ASCO

Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform New York/London – May 14, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: TIZIANA LIFE SCIENCES PLC 1b. Please...

Result of General Meeting

Tiziana Life Sciences plc ("Tiziana" or the "Company") At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue shares, to disapply pre-emption rights, replacement of option grants and adoption of...

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: TIZIANA LIFE SCIENCES PLC 1b. Please...

Total Voting Rights

For the purposes of the Disclosure Guidance and Transparency Rules, the Company is required to notify the market of the following: During the month of April 2020, 906,905 Ordinary Shares were issued to support the allotment and issue of sales of 181,381 on aggregate...